MAPT dsRNAi Composition for Selective Tau Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for tauopathies, such as Alzheimer's disease and frontotemporal dementia, are limited to symptom alleviation, and there is a need for agents that can selectively and efficiently inhibit or adjust the expression of the MAPT gene to effectively treat these disorders.
Innovation Solution
The development of RNAi compositions that target the MAPT gene, utilizing double-stranded ribonucleic acid (dsRNA) agents with specific nucleotide modifications to inhibit MAPT expression by at least 25% to 95%, thereby reducing Tau protein levels and addressing the underlying cause of tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for tauopathies, then symptom alleviation is achieved, but the underlying cause is not addressed and disease progression continues
Solution Approach 1:
The RNAi agent is designed to preemptively reduce MAPT gene expression before pathological Tau aggregation can progress, intervening in the disease mechanism at an earlier stage. The agent targets the genetic expression level to prevent the formation of toxic Tau aggregates that drive neurodegeneration.
Solution Approach 2:
The patent replaces conventional symptomatic treatment approaches with a molecular biology-based mechanism (RNA interference) that directly targets gene expression. This substitution enables specific inhibition of MAPT transcription at the molecular level, addressing the root cause rather than merely managing symptoms.
2Manufacturing precision
If RNAi agents are designed to inhibit MAPT expression, then Tau protein levels are reduced, but selective targeting and efficiency must be optimized
Solution Approach 1:
The RNAi agent incorporates localized nucleotide modifications at specific positions within the duplex structure. These modifications are not uniform throughout the entire sequence but are strategically placed to enhance particular functions such as target binding affinity, nuclease resistance, or cellular uptake while maintaining sequence-specific recognition of MAPT mRNA.
Solution Approach 2:
The patent systematically varies parameters including nucleotide sequence composition, modification types (e.g., 2'-O-methyl, phosphorothioate), modification positions, and duplex stoichiometry to optimize the balance between target inhibition efficiency and molecular stability. These parameter adjustments fine-tune the agent's properties for maximal therapeutic effect.
3Productivity
If dsRNA agents are used to target MAPT gene, then gene expression is inhibited by 25-95%, but off-target effects and safety must be managed
Solution Approach 1:
The RNAi agent uses a complementary copy of the target MAPT mRNA sequence (antisense strand) to achieve specific binding and silencing. This sequence complementarity ensures that only the intended target is affected, as the antisense strand is designed to match the unique sequence of MAPT transcripts, minimizing off-target binding to other genes.
Solution Approach 2:
The patent employs the RNA-induced silencing complex (RISC) as an intermediary mechanism. The dsRNA agent is processed by cellular machinery into small interfering RNAs that guide RISC to the target mRNA. This intermediary system provides an additional layer of specificity through sequence-dependent recognition and cleavage, reducing the risk of off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA agents effectively inhibit MAPT gene expression, leading to a significant reduction in Tau protein levels, potentially providing a therapeutic benefit for subjects with tauopathies by targeting the root cause of these neurodegenerative disorders.
Implementation Method 1
RNAi compositions, which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a MAPT gene
Data Source
AI summary
The disclosure relates to double stranded ribonucleic acid interference (dsRNAi) agents and compositions targeting a microtubule-associated protein tau (MAPT) gene, as well as methods of inhibiting expression of a MAPT gene and methods of treating subjects having a MAPT-associated disease or disorder, e.g., Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, or other tauopathies, using such dsRNAi agents and compositions.